TransMedics offers portable ex-vivo perfusion and assessment of donor organs for transplantation. The company was founded to address the need for organ transplantation. It focuses on transforming organ utilization, improving patient outcomes, and reducing transplant costs throughout the health care system. The platform develops technology for preserving organs used in the treatment of end-stage heart, lung, and liver failure. The company was founded in 1998 and is based in Andover, Massachusetts.
Missing: TransMedics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: TransMedics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing TransMedics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
TransMedics is included in 2 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
TransMedics has filed 38 patents.
Cardiac anatomy, Congenital heart defects, Cardiology, Transfusion medicine, Cardiovascular physiology
Cardiac anatomy, Congenital heart defects, Cardiology, Transfusion medicine, Cardiovascular physiology
Latest TransMedics News
Jan 20, 2023
USD 295 Million by 2026 | Organ Preservation Industry Trends, Share, Price, Demand, Analysis & Forecast Report by Facts & Factors The global Organ Preservation market size was valued at USD 201 million in 2020 and is expected to surpass USD 295 million by 2026, registering a CAGR of 5.9% during the forecast period (2021- 2026), as highlighted in a report published by Facts & Factors. The key market players are listed in the report with their sales, revenues and strategies are XVIVO Perfusion, TransMedics, 21st Century Medicine, CyroLife, Inc., Bridge to Life Ltd., OrganOx, Shanghai Genext Medical Technology, and Others. January 20, 2023 03:18 ET Deerfield Beach, Florida, UNITED STATES NEW YORK, United States, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Facts and Factors has published a new research report titled “Organ Preservation Market By Solution (University of Wisconsin (UW), Custodial HTK, Perfadex, & Others), By Organ Type (Kidneys, Liver, Lung, Heart, & Others), By Preservation Method (Static Cold Storage, Hypothermic Machine Perfusion, Normothermic Machine Perfusion, & Others), And By Regions - Global & Regional Industry Perspective, Comprehensive Analysis, and Forecast 2021 – 2026” in its research database. “According to the latest research study, the demand of global Organ Preservation Market size & share was valued at approximately USD 201 million in 2020. The market is expected to grow above a CAGR of 5.9% and is anticipated to reach over USD 295 million by 2026.” The report analyzes the organ preservation market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the global organ preservation market. Organ Preservation Market Overview: Organ preservation is the process of supplying transportation and preservation of organs for further use during a later period. Organ preservation measures usually come into the picture at the time of implementation of organ procurement surgical measures. Various methods are used for organ preservation such as hydrogen gas cylinder, electrolysis, or a hydrogen-generating agent. Please Check Out Our Free Sample Reports and Make a More Informed Decision: Get a Free Sample PDF of this Research Report for more Insights - https://www.fnfresearch.com/sample/organ-preservation-market-report (Before you plan to buy, sample reports are a great option to examine our in-depth studies or reports) Our Free Sample Report Consists of the Following: Introduction, Overview, and in-depth industry analysis are all included in the updated report. About 197+ Pages Research Report (Including Recent Research) Provide detailed chapter-by-chapter guidance on Request Updated Regional Analysis with Graphical Representation of Size, Share, and Trends Includes Tables and figures have been updated The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, Revenue Analysis, SWOT Analysis, Historic and Forecast Growth, Porter's 5 Forces Analysis Facts and Factors research methodology Key Insights from Primary Research As per the analysis, the organ preservation market is likely to grow above a CAGR of around 5.9% between 2021 and 2026. The Organ Preservation market size was worth around US$ 201 million in 2020 and is estimated to hit approximately US$ 295 million by 2026. Due to a variety of driving factors, the market is predicted to rise at a significant rate. Based on solution, Peradex leads the global market in terms of growth rate. Majority of the market shares was held by static cold storage in the technique segment. Among organ types, the lungs will witness the highest growth rate during the forecast period On the basis of region, the North America dominates the organ preservation market. Industry Growth Factors The global organ preservation market is expected to register a higher market growth during this iteration of the forecast period due to increasing incidences of multi-organ failures, rising geriatric population, and rising number of organ donations and organ donors to name a few. Additionally, a rising number of initiatives to encourage people for donating organs post-mortem coupled with an increasing number of key market players across the globe will increase the footprint of the global organ preservation market during the advent of the forecast period. Moreover, the increasing number of organ transplantation procedures coupled with increasing instances of cardiovascular diseases will boost the growth of the global organ preservation market during the advent of the forecast period. The global organ preservation market will be driven by increasing consumer awareness coupled with rising government initiatives and campaigns promoting organ donation measures to name a few. However, a higher cost of the medical procedure coupled with increasing religion-based concerns about transplantation will decrease the value of the global organ preservation market to some extent. Directly Purchase a copy of the report with TOC @ https://www.fnfresearch.com/buynow/su/organ-preservation-market-report Competitive Players The report contains qualitative and quantitative research on the global Organ Preservation Market, as well as detailed insights and development strategies employed by the leading competitors. The report also provides an in-depth analysis of the market's main competitors, as well as information on their competitiveness. The research also identifies and analyses important business strategies used by these main market players, such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts. Some of the main players in the global Organ Preservation market include; XVIVO Perfusion
TransMedics Frequently Asked Questions (FAQ)
When was TransMedics founded?
TransMedics was founded in 1998.
Where is TransMedics's headquarters?
TransMedics's headquarters is located at 200 Minuteman Road, Andover.
What is TransMedics's latest funding round?
TransMedics's latest funding round is Debt - III.
How much did TransMedics raise?
TransMedics raised a total of $318.73M.
Who are the investors of TransMedics?
Investors of TransMedics include CIBC Innovation Banking, Flagship Pioneering, Kleiner Perkins Caufield & Byers, Abrams Capital Management, InBio Ventures and 19 more.
Who are TransMedics's competitors?
Competitors of TransMedics include Suneva Medical, SynCardia Systems, Mercator MedSystems, Posit Science, NxStage Medical and 13 more.
Compare TransMedics to Competitors
Orqis Medical Corporation is a medical device company. It had developed the Orqis Extracorporeal Blood Pumping System, Model Bps-100.
GLevel is a seed stage partnership between Three Arch Partners and Incept which is a syndicate of medical device entrepreneurs and clinicians starting new opportunities in the medical device space.
CoRepair, Inc. is developing a radiofrequency (RF) device system for the treatment of congestive heart failure.
Verimetra aims to make medical instruments "smart" and manufacturers miniature thin film sensors used in medical applications that involve very small high end catheters. The Company designs and manufactures sensors using micro-electromechanical systems (MEMS) technology, which is the only method available that produces sensors small enough to be embedded in surgical devices without changing their basic form or function, allowing the company's customers to sell the same products, now "smart", without requiring the surgeon to use a new device. Verimetra aims to make medical devices "smart" by embedding (US Patent 6,494,882) a variety of small sensors at an place on or within the device. Simply stated, the company make "dumb" metal tools "smart". Examples include forceps, grippers, retractors, drills, and other surgical devices. Through the use of Verimetra's products, medical device manufacturers are able to deliver features and functionality that, depending on the medical procedure, improve outcomes, reduce risk and shorten patient recovery times. Verimetra's new product features are also used by manufacturers to strengthen their market position, enter new markets and maintain gross margins. Verimetra aims to give these manufacturers a way to accomplish these goals by adding features at a low cost without product redesign. Furthermore, in many instances, Verimetra's customers' goals will be met by the transformation of a re-usable product (one-time sale) into a smart disposable product (one sale per procedure).
C Change Surgical Llc is a medical device company. It had developed the Intratemp Solution Warmer.Introducing IntraTemp, it will take the uncertainty out of surgical fluids. IntraTemp defines the new standard of care in portable controlled-temperature for irrigation and lavage fluids. Instead of warming fluids away from where you are using them, IntraTemp is completely mobile, allowing for a more efficient way to guarantee the correct temperature to your patients. It will reduce risks for your patients and stress for your staff. It puts temperature control where you need it, when you need it. IntraTemp provides temperature data for chartable proof of quality care.
NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.